The global biopharmaceutical sector, clinical oncology networks, multi-lateral public health alliances, and national immunization frameworks are undergoing a highly synchronized expansion centered on early oncogenic prophylaxis, expanded cohort eligibility, and structural cancer elimination. The Human Papillomavirus (HPV) vaccine—a recombinant sub-unit formulation consisting of major...